171 related articles for article (PubMed ID: 37674872)
41. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
42. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
[TBL] [Abstract][Full Text] [Related]
43. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
[TBL] [Abstract][Full Text] [Related]
44. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling.
Mutai R; Goldvaser H; Shochat T; Peretz I; Sulkes A; Yerushalmi R
Oncology; 2019; 96(1):14-24. PubMed ID: 30253418
[TBL] [Abstract][Full Text] [Related]
46. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
48. Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system.
Martel S; Lambertini M; Simon R; Matte C; Prady C
Curr Oncol; 2018 Aug; 25(4):e311-e318. PubMed ID: 30111977
[TBL] [Abstract][Full Text] [Related]
49. Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization.
Ünal Ç; Özmen T; Ordu Ç; Uras C; Kara H; Gökmen E; Özdoğan M; Demircan O; Pilancı KN; Duymaz T; Özmen V
Eur J Breast Health; 2023 Oct; 19(4):325-330. PubMed ID: 37795003
[TBL] [Abstract][Full Text] [Related]
50. The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.
Iles K; Roberson ML; Spanheimer P; Gallagher K; Ollila DW; Strassle PD; Downs-Canner S
NPJ Breast Cancer; 2022 Mar; 8(1):27. PubMed ID: 35232996
[TBL] [Abstract][Full Text] [Related]
51. Oncotype DX and Prosigna in breast cancer patients: A comparison study.
Abdelhakam DA; Hanna H; Nassar A
Cancer Treat Res Commun; 2021; 26():100306. PubMed ID: 33444922
[TBL] [Abstract][Full Text] [Related]
52. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
53. Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients.
Huang Z; Qin Q; Xia L; Lian B; Tan Q; Yu Y; Mo Q
Cancer Manag Res; 2021; 13():587-593. PubMed ID: 33519238
[TBL] [Abstract][Full Text] [Related]
54. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
[TBL] [Abstract][Full Text] [Related]
55. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
56. Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.
Braun M; Kriegmair A; Szeterlak N; Andrulat A; Schrodi S; Kriner M; Hanusch C; Hamann M; Stoetzer O; Pölcher M
Breast Care (Basel); 2022 Jun; 17(3):288-295. PubMed ID: 35957951
[TBL] [Abstract][Full Text] [Related]
57. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
58. Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
Crager M; Wijayawardana SR; Gruver AM; Blacklock A; Russell C; Baehner FL; Sapunar F
Breast Cancer Res; 2022 Nov; 24(1):74. PubMed ID: 36320066
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre.
Davey MG; Ryan ÉJ; Abd Elwahab S; Elliott JA; McAnena PF; Sweeney KJ; Malone CM; McLaughlin R; Barry MK; Keane MM; Lowery AJ; Kerin MJ
Breast J; 2021 Jun; 27(6):521-528. PubMed ID: 33709552
[TBL] [Abstract][Full Text] [Related]
60. Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
Wang F; Reid S; Zheng W; Pal T; Meszoely I; Mayer IA; Bailey CE; Park BH; Shu XO
Clin Cancer Res; 2020 Jan; 26(1):101-109. PubMed ID: 31748278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]